$100.00
5mg / 5mg – Lyophilized *MUST BE RECONSTITUTED*
Introducing the CJC-1295/Ipamorelin blend – studied for its potential to enhance growth hormone levels. CJC-1295, a truncated peptide analogue of growth hormone-releasing hormone (GHRH), stimulates the natural release of growth hormone by activating the GHRH receptor. Ipamorelin, one of the most selective growth hormone secretagogues, acts as a potent agonist of the ghrelin/growth hormone secretagogue receptor. Research indicates that Ipamorelin can improve bone health, boost muscle repair and development, stimulate insulin release, and enhance bowel motility and gastric function.When combined, CJC-1295 and Ipamorelin exhibit synergistic effects, potentially leading to enhanced muscle growth, accelerated wound healing, improved metabolism, and better overall health outcomes.
The CJC-1295 / Ipamorelin Blend (5mg / 5mg) is a premier dual-peptide research formulation engineered to explore maximum growth hormone (GH) secretagogue synergy. By pairing a stable GHRH receptor agonist with a highly selective GHRP pentapeptide, this formulation serves as an advanced investigative tool for tracking accelerated lean tissue repair, bone density optimization, lipolysis, and enhanced metabolic efficiency in laboratory models.
Supplied as a stable, high-purity lyophilized powder blend in a single 10mg total mass vial. *MUST BE RECONSTITUTED FOR RESEARCH APPLICATIONS.* Restricted strictly to laboratory and in vitro evaluation.
Eterna Peptides presents a premium, high-purity dual blend of CJC-1295 No DAC (5mg) and Ipamorelin (5mg) lyophilized powder. This precisely balanced combination pairs a growth hormone-releasing hormone (GHRH) analog with a highly selective growth hormone secretagogue receptor (GHSR) agonist to explore receptor signaling synergy, cellular tissue repair, and metabolic optimization.
Mechanism of Action
The CJC-1295 / Ipamorelin formulation leverages two distinct pathways to stimulate the synthesis and pulsatile release of endogenous growth hormone ($GH$) without inducing receptor desensitization:
* **CJC-1295 No DAC (Modified GRF 1-29):** Acts as a highly stable agonist at the GHRH receptor in the anterior pituitary. By optimizing the first 29 amino acids of native GHRH, it resists rapid enzymatic breakdown ($DPP-IV$ cleavage), extending its experimental half-life while preserving natural physiological GH “pulses.”
* **Ipamorelin (Selective GHRP):** A potent pentapeptide that binds selectively to the ghrelin/growth hormone secretagogue receptor. Ipamorelin mimics ghrelin to trigger a clean, amplified release of GH from pituitary somatotrophs without altering baseline cortisol, prolactin, or aldosterone levels.
Research Applications
In preclinical and in vitro laboratory models, the CJC-1295 / Ipamorelin dual blend is heavily utilized to investigate:
* Synergistic receptor saturation mechanics that maximize endogenous growth hormone secretion compared to single-agent baselines.
* Accelerated cellular repair pathways, connective soft tissue remodeling, and myofibrillar protein synthesis.
* Bone mineral density optimization, collagen deposition, and structural joint repair dynamics.
* Metabolic alterations, including enhanced lipid breakdown (lipolysis) and improved deep sleep architecture models.
Our dual-blend vials undergo strict laboratory quality control validation to ensure an exact 1:1 component ratio, absolute structural purity, and dependable experimental reproducibility.
—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*
